Pivotal European Study Results Show Innovative Cancer Diagnostic Technology

By MedImaging International staff writers
Posted on 27 Dec 2016

A medical imaging company that pioneered a novel opto-acoustic breast-imaging technology has released new down-classification and up-classification data from a European post-market surveillance and clinical follow-up study called MAESTRO.

The final results of the MAESTRO study are expected to be released in early 2017, while the results from another large-scale trial of the technology in the US called PIONEER that includes more than 2,000 patients are planned to be released in the second half of 2017.

Image: The diagram describes the principle of the photoacoustic effect and imaging used in the SENO Medical Imagio modality (Photo courtesy of Ultrasonography).

Seno Medical Instruments (San Antonia, TX, USA) is developing and commercializing the Imagio opto-acoustic breast-cancer diagnostics imaging modality. The solution combines results from the Imagio system with ultrasound scans to produce functional and anatomical images of the breast, including a color map for suspicious breast masses, with standard anatomic ultrasound images. The new modality could help radiologists confirm or rule out malignancy in breast tumors without the use of ionizing radiation or contrast agents.

Medical Director of SENO Medical, Thomas Stavros, MD, said, "The Imagio breast imaging system represents a significant advance to improve the diagnoses of breast cancer by helping to determine the appropriate classification of breast masses. The presentation of the histological data will be of particular interest to the oncology community as it will identify a correlation between the opto-acoustic imaging findings and histologic grade of the breast masses."

Related Links:
Seno Medical Instruments